Date: 2015-07-01
Type of information: Nomination
Compound:
Company: Sarepta Therapeutics (USA - MA)
Therapeutic area: Rare diseases - Genetic diseases - Neuromuscular diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On July 1, 2015, Sarepta Therapeutics announced Henri Termeer, industry leader and former CEO of Genzyme, will be a key advisor to the Company. Henri Termeer is the former chairman, president and chief executive officer of Genzyme Corporation, where he served for nearly three decades until retiring in 2011 following the acquisition of Genzyme by Sanofi in a transaction valued at more than $20 billion. Mr. Termeer continues to be very active in the areas of humanitarian assistance, policy issues, and innovation in providing access to healthcare. Henri and his wife, Belinda, founded the Termeer Center for Targeted Therapies at Massachusetts General Hospital in 2012. He serves on the boards of numerous scientific and healthcare institutions. He is a Fellow of the American Academy of Arts and Sciences.
Financial terms:
Latest news:
